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Abstract
Introduction: In recent genome-wide association studies for psoriatic arthritis (PsA) and psoriasis vulgaris, common
coding variants in the TRAF3IP2 gene were identified to contribute to susceptibility to both disease entities. The risk
allele of p.Asp10Asn (rs33980500) proved to be most significantly associated and to encode a mutant protein with
an almost completely disrupted binding property to TRAF6, supporting its impact as a main disease-causing variant
and modulator of IL-17 signaling.
Methods: To identify further variants, exons 2-4 encoding both known TNF-receptor-associated factor (TRAF)
binding domains were sequenced in 871 PsA patients. Seven missense variants and one three-base-pair insertion
were identified in 0.06% to 1.02% of alleles. Five of these variants were also present in 931 control individuals at
comparable frequency. Constructs containing full-length wild-type or mutant TRAF3IP2 were generated and used to
analyze functionally all variants for TRAF6-binding in a mammalian two-hybrid assay.
Results: None of the newly found alleles, though, encoded proteins with different binding properties to TRAF6, or
to the cytoplasmic tail of the IL-17-receptor a-chain, suggesting that they do not contribute to susceptibility.
Conclusions: Thus, the TRAF3IP2-variant p.Asp10Asn is the only susceptibility allele with functional impact on
TRAF6 binding, at least in the German population.
Introduction
Recent genome-wide association studies (GWASs) for
psoriatic arthritis and psoriasis vulgaris have been quite
successful and revealed more than 25 new susceptibility
loci [1-7] characterizing psoriatic arthritis (PsA), mainly
as an immune-mediated disease that is also affected by
barrier proteins. One new PsA and psoriasis-susceptibil-
ity gene, TRAF3IP2, codes for the adaptor protein ACT1
(nuclear factor-B activator 1), a regulator of the NF-B
pathway involved in IL-17 signaling. We were able to
identify the common coding variant p.Asp10Aspn
(rs33980500) as the disease-causing allele with evidence
from association findings at single nucleotide poly-
morphism (SNP) and haplotype levels, as well as binding
studies of ACT1 with its interaction partner TRAF6 [2]
(Figure 1). However, despite the exponentially increased
knowledge of PsA and psoriasis susceptibility, the sum
of the currently identified genetic risk factors does not
explain the entire genetic contribution to disease.
At the common susceptibility gene IL23R,c o d i n gf o r
interleukin-23 receptor for Crohn disease, low-frequency
variants have been identified as protective factors, and
their effects turned out to be larger than those of common
variants and accounted for a greater portion of genetic
contribution [8]. To find out whether low-frequency cod-
ing variants in TRAF3IP2 contribute to PsA susceptibility,
we sequenced exons encoding TRAF-binding domains
(Figure 1) [9] and studied their association with PsA as
well as the functional consequences of the respective
amino acid changes on interaction with TRAF6 and the
interleukin-17 receptor a (IL17-RA).
Materials and methods
Study population
We analyzed a case-control study comprising 871 PsA
patients. A subset of 764 patients was described previously
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any medium, provided the original work is properly cited.[2]. All patients fulfilled the recently defined CASPAR (for
ClASsification of Psoriatic ARthritis) criteria [10] and were
recruited between 2002 and 2011 exclusively by board-cer-
tified rheumatologists at five different rheumatology
departments in Germany. In comparison to the previously
described cohort, clinical characteristics were very similar:
the mean (SD) age of onset for PsV was 28.3 ± 13.3 years;
60.8% of the patients were men. For 78% of the patients,
the diagnosis of PsA was made ≥ 3 years before recruit-
ment, and 96% of patients had a skin involvement ≥ 3
years before study inclusion. Peripheral joint involvement
was detectable in the majority of cases (827 or 94.8%); this
was oligoarticular in 183 patients and polyarticular in 644
(21.0% and 73.8% of the entire cohort, respectively). Diag-
nosis of spinal involvement was based on symptoms of
inflammatory back pain, characteristic clinical signs of
restricted vertebral movement and/or sacroiliac pain on
physical examination, and a subsequent confirmation by
radiographic signs of sacroiliitis or spondylitis or both.
Spinal involvement was observed in 204 patients, account-
ing for 23.4% of the PsA cohort. In these patients, sacroilii-
tis or spondylitis or both were partly associated with
concomitant peripheral joint disease.
The 931 German control individuals were healthy
blood donors and the same as previously reported [2].
Ethical approvals for all German studies were obtained
from the Ethics Committees of the medical faculties of the
Universities of Erlangen, Münster, and Frankfurt/Main.
All probands gave written informed consent. The investi-
gations were conducted according to the Declaration of
Helsinki principles.
Sequencing
All PsA patients were sequenced for exons 2-4 coding
for TRAF-binding domains. Mainly intron-based pri-
mers for four amplicons were designed with Primer 3
(v.0.4.0) [11]. In general, Sanger sequencing was per-
formed, as described before [12], with the following
changes: thermocyclers were Thermo Multiblock (Ther-
moFisher Scientific, Ulm, Germany); the robotic system
for PCR (polymerase chain reaction) clean-up as well as
for sequencing reactions was Beckman-Coulter Biomek
N x p( k i tf o rP C Rc l e a n - u p :A g e n c o u r tA M P u r e ;k i tf o r
sequencing reactions: CleanSEQ; Beckman-Coulter, Kre-
feld, Germany). Sequences were analyzed with the Soft-
ware Sequencher versus 4.10.1 (Gene Codes, Ann
Arbor, MI, USA). Genotyping rates of the four ampli-
cons were between 99.8% and 100%. Variants were
named according to the usual naming conventions with
regard to TRAF3IP2 reference sequence NM_147686
(coding for 565 amino acids).
Analysis of variants in controls
Control individuals were genotyped for all missense
variants as well as the 3bp-insertion with self-designed
TaqMan assays (Life Technologies, Carlsbad, CA, USA),
as previously described [2]. Missing genotypes or carriers
of low-frequency variants were resequenced, resulting in a
genotyping rate of 100% for seven variants and 99.8% for
the further one.
Statistics
Fisher Exact test, as implemented in R (version 2.13.1)
[13], was used for comparison of frequency distributions
between cases and controls.
Protein-binding analyses in mammalian two-hybrid
system
A mammalian two-hybrid assay (Stratagene) was applied
to analyze the interaction of wild-type and mutant protein
ACT1 of TRAF3IP2 with TRAF6 and IL-17RA, as
described before [2]. As a change to previous analyses,
full-length TRAF3IP2 mRNA (coding for amino acid resi-
dues 1 through 565) was amplified from reverse-tran-
scribed cDNA of the chondrocyte cell line T/C28a4 by
using 5’-TGAATTCATGAACCGAAGCATTCCTGTG-3’
Figure 1 Interleukin (IL)-17A/IL17F binds to the heterodimeric
IL-17R and leads to its signaling. Signaling includes recruitment
of nuclear factor-B activator 1 (ACT1) via SEFIR domains (red ovals).
Activation of ACT 1 encoded by TRAF3IP2 allows binding to TRAF6
via TNF receptor-associated factor (TRAF)-binding domains (yellow
ovals); this activates NF-B as well as proinflammatory cytokines.
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AG-3’. The cytoplasmic tail of IL-17RA (amino acid resi-
dues 343-667, NM_014339) was amplified from reverse-
transcribed cDNA of the human macrophage cell line
THP-1 by using 5’-AGGATCCATGACCTGGAGGC-
TAGCTGGGCCTGGAA-3’ and 5’-AGCGGCCGCT-
CAGGTGTGGAGGGGCTGCGGCGCTGGCTGA-3’,
a n dc l o n e di n t ot h eBamHI/NotIs i t eo ft h ep C M V - B D
bait vector. HEK 293 cells (1 × 10
4) were grown in 96-well
white tissue-culture plates (Greiner) for 24 hours, and the
bait and prey vectors (25 ng each) were co-transfected
with a firefly luciferase reporter (250 ng) by using jetPEI
reagents according to the supplier’s instructions (PeqLab).
Transfection efficiency was controlled by co-transfecting a
renilla luciferase plasmid (5 ng, pRL-TK vector; Promega).
At 48 hours after transfection, luciferase activity of quad-
ruplicate wells was measured by using the Dual Glo Assay
System (Promega) on a Mithras LB940 plate reader (Bert-
hold Technologies). Assays were performed ≥ 5 times.
For functional testing of the two common as well as the
newly identified rare coding variants of TRAF3IP2 [2],
constructs were generated by site-directed mutagenesis by
using the QuickChange site-directed mutagenesis kit
(Stratagene). Quality control of all vectors was performed
with DNA sequencing. The firefly luciferase values were
normalized to the Renilla values. Statistical significance
was determined by using an unpaired Student t test.
Results
Sanger sequencing in 871 PsA patients revealed eight low-
frequency variants: one 3-bp insertion and seven missense
variants, one of them being the known SNP rs61756667
(minor allele frequency of 0.10% in the database), as indi-
cated in Table 1. Allele frequencies ranged between 0.06%
and 1.03% in PsA cases and 0 to 0.54% in control indivi-
duals, respectively. Distributions of allele frequency for
single low-frequency variants as well as the sum of the
eight variants (P = 0.493) did not show significant differ-
ences between cases and controls.
Because our case-control study of ~900 individuals was
of limited power to exclude association to very-low-
frequency variants (for example, found on one allele of
one patient), we investigated the impact of amino acid
changes encoded by the new TRAF3IP2-variants on func-
tional properties of the ACT1 protein also by mammalian
two-hybrid technology. None of the amino acid muta-
tions in the full-length constructs of the new TRAF3IP2
coding variants exhibited any influence on TRAF6 bind-
ing (Figure 2). Also, TRAF6 interaction of the common
coding variant rs13190932 (p.Arg74Trp) was comparable
to wild-type, in agreement with earlier results obtained in
assays using shortened TRAF3IP2 constructs [2]. In con-
trast, the analysis of a full-length TRAF3IP2 construct,
containing the earlier described disease-causing variant
rs33980500 (p.Asp10Asn), revealed a nearly completely
disrupted interaction with TRAF6 (~90%), thereby con-
firming previous analyses. Moreover, the ability to inter-
act with the cytoplasmic IL-17RA domain did not differ
between ACT1 proteins encoded by either wild-type
TRAF3IP2 or by any of its low-frequency variants. In this
respect, p.Asp10Asn did not cause different results com-
pared with other TRAF3IP2 variants.
Table 1 Association analysis of new variants
Coding position Protein position Position hg19 Allele 871 PsA patients 931 control individuals P (Fisher Exact)
n % n %
c.105_106 InsACC p.Pro35dup 111913185 Ins 2 0.11 3 0.16 1
WT 1,740 99.89 1,859 99.84
c.281G > A (rs61756667) p.Ser94Asn 111913009 A 1 0.06 4 0.21 0.376
G 1,737 99.94 1,858 99.79
c.350C > T p.Ala117Val 111912940 T 1 0.06 0 0 0.483
C 1,737 99.94 1,858 100.00
c.649C > A p.Pro217Thr 111912641 A 18 1.03 10 0.54 0.127
C 1,724 98.97 1,852 99.46
c.691C > T p.Leu231Phe 111912599 T 2 0.11 1 0.05 0.613
C 1,740 99.89 1,861 99.95
c.746A > G p.Gln249Arg 111912544 G 1 0.06 0 0 0.483
A 1,741 99.94 1,862 100.00
c.1058G > C p.Gly353Ala 111896989 C 1 0.06 0 0 0.483
G 1,741 99.94 1,862 100.00
c.1184A > G p.Asn395Ser 111896863 G 3 0.17 7 0.38 0.346
A 1,739 99.83 1,855 99.62
WT, wild type. Names, position on chromosome 6, and count/frequency of wild-type alleles/low-frequency alleles of new variants in PsA patients and control
individuals are shown, as well as the P value of Fisher Exact test.
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Our in-depth sequencing of TRAF-binding domains in
TRAF3IP2 revealed a number of new low-frequency var-
iants in PsA patients occurring at a similar frequency in
control individuals. This finding is not unexpected,
because, for example, newly identified low-frequency var-
iants in most of the susceptibility genes identified in
GWAS and sequenced for Crohn disease [8] or type I
diabetes [14] were not associated with disease. Further
evidence that our newly identified coding variants do not
cause disease was derived from functional analyses: none
of the variants leading to amino acid changes in the
respective ACT1 proteins affected TRAF6 interaction.
Reassuringly, we could confirm previous results of a dra-
matically reduced TRAF6 binding for the ACT1 variant
harboring the disease-causing variant p.Asp10Asn under
assay conditions analyzing full-length TRAF3IP2-tran-
scripts (Figure 2). Binding of ACT1 to the cytoplasmic
domain of IL-17RA is mediated via a C-terminal SEFIR
domain that remained conserved in wild-type configuration
in all investigated TRAF3IP2 constructs (Figures 1 and 2).
Accordingly, a rather limited a priori likelihood existed to
detect major differences in IL-17RA-binding properties of
the investigated mutant TRAF3IP2 constructs, although an
indirect modulatory effect of conformational changes
induced by the distantly located mutations in the TRAF-
binding domains could not be entirely excluded. However,
our studies did not reveal an altered IL-17RA interaction
for any of the nine investigated coding variants.
Conclusions
Our data indicate that the common variant rs33980500
(p.Asp10Aspn) is the only risk allele for PsA with func-
tional impact on TRAF6 binding, at least in the German
population.
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Figure 2 Binding of ACT1 and its mutant variants to TNF receptor-associated factor (TRAF)6 and interleukin (IL)-17RA. Interaction of
wild-type TRAF3IP2/ACT1 and its mutant variants with either TRAF6, upper panel, or IL-17RA, lower panel, was determined by mammalian two-
hybrid system. The TRAF3IP2 mutant p.Asp10Asn showed a significantly reduced binding to TRAF6. Common coding variants indicated by
underlined and italicized letters. *P < 0.005, when compared with wild-type TRAF3IP2.
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